Gynecomastia in Men Over 40: Causes, the TRT Connection, and What Actually Shrinks It

Gynecomastia, the growth of true breast gland tissue in men, shows up in roughly a third of healthy adult men and in a larger share of men over 50. It is driven by a shift in the balance between estrogen and testosterone, often nudged along by body fat, medications or testosterone therapy. Tissue that is under about 12 months old often responds to treatment, while older tissue turns fibrotic and usually needs surgery.

Gynecomastia in men over 40 is the growth of real breast gland tissue, usually a firm, rubbery disc sitting directly under the nipple, and it is far more common than most men assume. Frank Nuttall examined 214 healthy men and reported in the Journal of Clinical Endocrinology and Metabolism in 1979 that 36 percent had palpable breast tissue. Later hospital surveys of older men found rates above 50 percent in men in their 50s, 60s and 70s.

Most gynecomastia in midlife men is benign, and a large share is reversible if the cause is found early. The problem is timing. Breast gland tissue goes through an active, tender growth phase and then gradually scars into fibrous tissue that no pill can shrink. A man who notices a sore lump behind one nipple and waits a year to mention it has often waited out the window when medication works best.

Gynecomastia is growth of glandular breast tissue, while pseudogynecomastia is ordinary fat deposited on the chest with no extra gland. The two often look alike in the mirror. The difference shows up under the fingers: true gynecomastia feels like a firm, rubbery or slightly gritty disc centered under the nipple and areola, while chest fat feels soft and uniform with no distinct edge.

A simple pinch test helps tell gynecomastia from fat. Lying flat on the back, a man can place a thumb and forefinger on either side of the nipple and slowly bring them together. With fat alone, the fingers meet with nothing in between. With gynecomastia, they stop at a mound of tissue roughly 2 centimeters or more across. Many men over 40 carrying extra weight have both at once, which matters because fat loss will shrink the fatty part but rarely the gland.

Gynecomastia becomes more common after 40 because the balance between testosterone and estrogen in breast tissue slowly tips toward estrogen. Total testosterone falls by roughly 1 percent a year from midlife, and sex hormone binding globulin rises, so free testosterone falls faster than the total number suggests. Estradiol, in contrast, stays roughly steady or rises, because it is made from testosterone by the aromatase enzyme in fat tissue.

Body fat is the main amplifier of that estrogen shift. Aromatase activity rises with total body fat and especially with abdominal fat, so a man who gains 15 kilograms between 35 and 50 converts more of his testosterone into estradiol at the same time that his testosterone output is drifting down. Breast gland cells carry estrogen receptors and androgen receptors. When the estrogen signal outweighs the androgen signal for months at a time, the ducts and surrounding tissue grow.

The cause breakdown above comes from Glenn Braunstein's reviews of gynecomastia in the New England Journal of Medicine, which remain the most cited reference for this question. Medications account for somewhere between 10 and 25 percent of cases depending on the series, which is why a full medication list is the first step in any workup. Testicular tumors are rare, at about 3 percent, but they are the reason a testicular exam belongs in every evaluation.

The medications most strongly linked to gynecomastia in men over 40 are spironolactone, antiandrogens used for prostate cancer, 5-alpha reductase inhibitors, and anything that adds estrogen or hCG. Spironolactone blocks androgen receptors and is one of the most common culprits in men treated for heart failure or high blood pressure. Switching to eplerenone, a more selective drug in the same class, usually stops the problem from progressing.

Finasteride and dutasteride, used for prostate enlargement and hair loss, raise the risk of gynecomastia modestly, with rates in the low single digits in large prostate trials. Other drugs on the list include ketoconazole, cimetidine, digoxin, some antipsychotics that raise prolactin, and anabolic steroids. Heavy alcohol use contributes through liver damage, which slows estrogen clearance. A man should not stop a prescribed drug on his own; the prescriber can often swap to an alternative with less hormonal effect.

Testosterone replacement therapy can cause gynecomastia in a minority of men, usually when doses produce high peaks of testosterone that are then converted into high peaks of estradiol. The risk is greatest with large, infrequent injections, such as 200 milligrams every two weeks, which create a spike in the first few days after each shot. Men with more body fat convert more testosterone into estradiol and are more prone to the problem.

Smaller, more frequent testosterone injections reduce the estradiol spikes that drive TRT-related gynecomastia. Splitting a weekly dose into two injections, or moving to daily gels, keeps blood levels flatter. hCG, often added to TRT to preserve testicular function, also raises estradiol and can contribute. Early warning signs on TRT are nipple tenderness or itching in the first one to three months, and that is the moment to check estradiol and adjust the protocol rather than wait for a lump.

Gynecomastia in adult men can go away on its own if the trigger is removed while the tissue is still in its early, active phase. In the first 6 to 12 months, the gland is made of growing ducts and loose, inflamed tissue, which is why it is often tender. Stopping an offending drug, adjusting TRT or losing significant body fat during this period can lead to partial or full regression over several months.

After about 12 months, gynecomastia tissue becomes largely fibrotic and rarely regresses with medication. The ducts stop growing, the surrounding tissue is replaced by dense collagen, and estrogen receptors matter much less. This is the main reason endocrinologists push for early evaluation. A painless lump that has been present for two years is not an emergency, but it is also unlikely to shrink with any drug.

Tamoxifen, a selective estrogen receptor modulator, is the medication with the best evidence for shrinking early gynecomastia in men. Tamoxifen blocks estrogen at the breast while leaving estrogen action elsewhere largely intact. The usual off-label dose in studies is 10 to 20 milligrams a day for 3 to 6 months, and case series in adult men have reported partial or complete regression in most patients when the tissue was recent and tender.

Anastrozole performs poorly against gynecomastia despite its popularity. Lesley Plourde and colleagues randomized 80 adolescent boys to anastrozole or placebo and reported in the Journal of Clinical Endocrinology and Metabolism in 2004 that anastrozole did no better than placebo at reducing breast volume. In men on bicalutamide, the Boccardo trial found gynecomastia in 51 percent of men on anastrozole versus 10 percent on tamoxifen. Raloxifene, another receptor modulator, has shown promise in small studies, mostly in younger patients.

Surgery is the right answer for gynecomastia that has been present for more than a year, that did not respond to treating the cause, or that causes ongoing pain or distress. The standard operation combines liposuction to remove surrounding fat with a small incision at the lower edge of the areola to cut out the firm gland, which liposuction alone cannot remove. Most procedures are outpatient, and men usually return to desk work within a week.

Surgeons grade gynecomastia with the Simon scale, which runs from grade I for small enlargement without excess skin to grade III for marked enlargement with sagging skin. Grades I and IIa usually need only gland removal and liposuction. Grades IIb and III may also need skin removal, which leaves longer scars. Recurrence after surgery is uncommon, but it can happen if the original hormonal cause, such as a high-estradiol TRT protocol, is never fixed.

A man over 40 with new gynecomastia should get a physical exam including the testicles, a medication review, and a short panel of morning blood tests. The usual panel covers total and free testosterone, estradiol, LH, FSH, prolactin, beta hCG, TSH, and liver and kidney function. A high hCG or a very high estradiol points toward a tumor and prompts a testicular ultrasound. A hard, one-sided or off-center lump calls for breast imaging, usually mammography with ultrasound in men over 25.

Continue Reading

Related Articles

Hormones

Estradiol in Men: Why Crushing Your Estrogen Is the Most Common TRT Mistake

12 min read

Read Article →

Hormones

HCG on TRT: Testicular Function, Fertility, and What the Signal Is Doing

13 min read

Read Article →

Hormones

DHT and Hair Loss on TRT: What the Conversion Actually Does

13 min read

Read Article →